Related Experiment Video

Updated: Feb 23, 2026

Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

8.5K

Corrigendum: Can we deliver randomized trials of focal therapy in prostate cancer?

Hashim U Ahmed, Viktor Berge, David Bottomley

    Nature Reviews. Clinical Oncology
    |September 13, 2017
    PubMed

    More Related Videos

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

    Published on: November 7, 2025

    916
    Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies08:34

    Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

    Published on: February 6, 2019

    21.2K

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    9.0K
    Blinding01:11

    Blinding

    Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
    4.0K